Patient online report of selective serotonin reuptake inhibitor-induced persistent postwithdrawal anxiety and mood disorders

Psychotherapy and Psychosomatics

Volumn 81, Issue 6, 2012, Pages 386-388

  Belaise, Carlotta ^a   Gatti, Alessia ^a   Chouinard, Virginie Anne ^b   Chouinard, Guy ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SERTRALINE;

AGITATION; ANXIETY DISORDER; BIPOLAR DISORDER; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LETTER; MAJOR DEPRESSION; MEMORY DISORDER; MOOD DISORDER; NAUSEA; ONLINE MONITORING; PANIC; PRIORITY JOURNAL; SELF REPORT; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ANXIETY DISORDERS; FEMALE; HUMANS; INTERNET; MALE; MOOD DISORDERS; SELF REPORT; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84865857237     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000341178     Document Type: Letter

References (10)

1. Schifano F, D'Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, Di Melchiorre G, Di Furia L, Farre M, Flesland L, Mannonen M, Majava A, Pagani S, Peltoniemi T, Siemann H, Skutle A, Torrens M, Pezzolesi C, van der Kreeft P, Scherbaum N: Is there a recreational misuse poten-tial for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011; 80:118-122.
2. Fontaine R, Chouinard G, Annable L: Rebound anxiety in anxious pa-tients after abrupt withdrawal of benzodiazepine treatment. Am J Psy-chiatry 1984; 141:848-852. (Pubitemid 14078994)
3. Chouinard G: Rebound anxiety: Incidence and relationship to subjec-tive cognitive impairment. J Clin Psychiatry 1986; 4:12-16.
4. Chouinard G: Severe cases of neuroleptic-induced supersensitivity psy-chosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991; 5:21-33.
5. Shoenberger D: Discontinuing paroxetine: a personal account. Psycho-ther Psychosom 2002; 71: 237-238. (Pubitemid 34827828)
6. Zajecka J, Tracy KA, Mitchell S: Discontinuation symptoms after treat-ment with serotonin reuptake inhibitors: a literature review. J Clin Psy-chiatry 1997; 58: 291-297. (Pubitemid 27362484)
7. Bhanji NH, Chouinard G, Kolivakis T, Margolese HC: Persistent tar-dive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Can J Clin Pharmacol 2006; 13:e69-74. (Pubitemid 46165600)
8. Fava GA, Bernardi M, Tomba E, Rafanelli C: Effects of gradual discon-tinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007; 10: 835-838. (Pubitemid 350035823)
9. Chouinard G, Chouinard VA: Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 2008; 77:69-77. (Pubitemid 351172096)
10. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB: Selective se-rotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77-87. (Pubitemid 28305526)